在患有喘的儿科患者中发现和治疗持续的小呼吸道功能障碍:回顾性队列研究
Lulu Zhang1, Zhou Fu1, Hua Deng2
1Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, NO.136, Zhongshan Second Road, 400014, Chongqing, China.
患有喘的儿童持续的小呼吸道功能障碍与特定的风险因素和更高的FeNO水平有关. 像ICS/LABA这样的组合疗法显示出比单独ICS更好的改善.
科学领域:
- 儿科呼吸系统医学 儿科呼吸系统医学
- 过敏和免疫学 过敏和免疫学
- 肺部病理学 肺部病理学
背景情况:
- 喘包括严重的炎症和小气道的气道改造.
- 持续的小呼吸道功能障碍 (p-SAD) 是儿科喘的一个关键问题.
- 了解p-SAD预测因子和治疗疗效对于临床管理至关重要.
研究的目的:
- 调查风险因素和空气中排出的氧化 (FeNO) 的分数度,以预测患有喘的儿童的p-SAD.
- 为了比较不同喘治疗方式对p-SAD的有效性.
- 确定用于区分小儿喘患者p-SAD的关键指标.
主要方法:
- 对248名患有喘的儿童 (4至11岁) 进行了回顾性队列研究.
- 用二进制后勤回归和斯皮尔曼等级相关性来分析风险因素和相关性.
- 接收器操作特征 (ROC) 曲线分析了FeNO对p-SAD的预测值.
主要成果:
- 定期治疗的年龄较大,症状发作的年龄较小,使用ICS/ICS/LABA的时间较长,喘控制较差,增加了p-SAD风险.
- 小气道功能参数与FeNO (FeNO200) 和大气管/小气管氧化 (CaNO) 有负相关.
- FeNO200和CaNO证明了p-SAD的预测价值,综合分析显示了高准确度.
结论:
- 患有p-SAD的儿童喘与特定的临床因素和升高的FeNO水平有关.
- FeNO200和CaNO,结合小气道功能指标,可以帮助区分p-SAD.
- 吸入性皮质类固醇/长效β-agonist (ICS/LABA) 组合治疗比单独的ICS更有效地改善了小呼吸道功能障碍.
相关概念视频
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
COPD: Management Using Bronchodilators and Corticosteroids
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation


